Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier

Human Psychopharmacology

Volumn 20, Issue 2, 2005, Pages 149-153

  Ejsing, Thomas B ^a   Linnet, Kristian ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Blood brain barrier; Drug drug interactions; Nortriptyline; P glycoprotein

Indexed keywords

10 HYDROXYNORTRIPTYLINE; CYCLOSPORIN A; GLYCOPROTEIN P; NORTRIPTYLINE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; ULTRAVIOLET RADIATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MALE; NORTRIPTYLINE; P-GLYCOPROTEIN; RATS; RATS, WISTAR; RISPERIDONE; TISSUE DISTRIBUTION;

EID: 14944375269     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.667     Document Type: Article

References (19)

1. Boulton DW, DeVane CL, Liston HL, Markowitz JS. 2002. In vitro P-glycoprotein affinity for atypical and conventional antipsychoties. Life Sci 71: 163-169.
2. Chen C, Hanson E, Watson JW, Lee JS. 2003. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31: 312-318.
3. Choo EF, Leake B, Wandel C, et al. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28: 655-660.
4. Dagenais C, Graff CL, Pollack GM. 2004. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67: 269-276.
5. Ford JM, Hait WN. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199.
6. Fromm MF. 2000. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of oral drugs. Int J Clin Pharmacol Ther 38: 69-74.
7. Lin JH. 2004. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today 40: 5-22.
8. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. 1997. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100: 2430-2436.
9. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K. 1998. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20: 380-384.
10. Schinkel AH. 1997. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8: 161-170.
11. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3-29.
12. Task Force on the Use of Laboratory Tests in Psychiatry. 1985. Tricyclic antidepressants - blood level measurements and clinical outcome: an APA Task Force Report. Am J Psychiatry 142: 155-162.
13. Tsai TH, Liu SC, Tsai PL, Ho LK, Shum AYC, Chen CF. 2002. The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study. Br J Pharmacol 137: 1314-1320.
14. Uhr M, Grauer MT. 2003. abcblab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 37: 179-185.
15. Uhr M, Grauer MT, Holsboer F. 2003. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdrlab) P-glycoprotein gene disruption. Biol Psychiatry 54: 840-846.
16. Uhr M, Steckler T, Yassouridis A, Holsboer F. 2000. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22: 380-387.
17. Van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. 1996. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 88: 994-999.
18. Wang J, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. 2004a. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl) 173: 132-138.
19. Wang J, Taylor R, Ruan Y, Donovan JL, Markowitz JS, DeVane CL. 2004b. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29: 551-557.